Developer docs
API playgroundTry for free, no card

Search company profiles

Biohaven

Full company profile

uuid00exdu6

Namestring
Biohaven
Legal namestring
Biohaven, Ltd.
Websiteurl
biohaven.com
Company typeenum
Public
Founded yearint
2023
Descriptiontext

Biohaven is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut (incorporated as Biohaven, Ltd. in the British Virgin Islands, with U.S. operations through Biohaven Pharmaceuticals, Inc.), that was spun out of Pfizer's 2023 acquisition of the original Biohaven and concurrently listed on the NYSE under ticker BHVN. The company employs 251-500 staff across offices in New Haven, Cambridge, and Pittsburgh, and is led by Chairman & CEO Vlad Coric, M.D. Biohaven is developing a diversified pipeline of drug candidates across four therapeutic areas — immunology, obesity, neuroscience, and oncology — supported by five proprietary technology platforms: MoDE (Molecular Degraders of Extracellular Proteins), TRAP (Targeted Removal via the asialoglycoprotein receptor), Kv7 ion channel modulation, MATE antibody-drug conjugate chemistry, and PKM2 metabolic modulation.

The pipeline includes late-stage clinical candidates BHV-1300 (MoDE degrader for Graves' disease, >80% pathogenic IgG reduction), BHV-1400 (TRAP degrader for IgA nephropathy, up to 81% Gd-IgA1 reduction), opakalim/BHV-7000 (Kv7.2/7.3 activator for epilepsy), taldefgrobep alfa (myostatin-activin inhibitor for obesity), BHV-1510 (Trop2 ADC combined with Regeneron's cemiplimab in solid tumors), BHV-1530 (FGFR3 ADC in urothelial cancer), BHV-8000 (TYK2/JAK1 inhibitor in Parkinson's), BHV-2100 (TRPM3 antagonist in pain), and first-in-human BHV-8100 (oral PKM2 modulator). A preclinical MoDE/TRAP portfolio extends into myasthenia gravis, Type 1 diabetes, pemphigus, and cardiomyopathies.

Biohaven generates no product revenue as of Q1 2026 (net loss of $130.5 million, a 41% improvement from $221.7 million in Q1 2025) and has no commercialized products following the divestiture of its legacy migraine franchise (Nurtec ODT, Zavzpret) to Pfizer. The company is pre-revenue and intends to monetize through future U.S. pharmaceutical distribution (specialty pharmacies, wholesalers, hospital networks) and potential licensing or co-development partnerships with large pharma, evidenced by its ongoing Regeneron combination collaboration. Strategic cost optimization announced in 2026 targets a ~60% reduction in annual direct R&D spend as the company prioritizes late-stage degraders, Kv7, and obesity programs following a November 2025 FDA Complete Response Letter on troriluzole for spinocerebellar ataxia and a December 2025 Phase 2 failure of opakalim in major depressive disorder.

Short descriptiontext

Biohaven is a clinical-stage biopharmaceutical company developing novel therapies across immunology, obesity, neuroscience, and oncology using proprietary platforms including MoDE and TRAP protein degraders, Kv7 ion channel modulators, and MATE ADC technology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNew Haven, United States
HQ citystring
New Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceutical, protein degradation therapeutics, autoimmune disease treatments, epilepsy drug development, antibody-drug conjugates
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Biohaven is a clinical-stage biopharmaceutical company with no current revenue from product sales. The company is developing multiple late-stage clinical candidates and has not yet commercialized any products. Historically, the company developed migraine treatments (Nurtec ODT and Zavzpret) that were sold to Pfizer as part of the original Biohaven acquisition.

finance.yahoo.com
2Drug Development Partnerships/Licensing
TypeLicensing Royalties
Description

Potential future revenue from licensing agreements or co-development partnerships for its proprietary platforms and pipeline candidates. The company may pursue partnerships for global commercialization of its clinical candidates.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Biohaven is a clinical-stage biopharmaceutical company developing life-changing treatments across immunology, obesity, neuroscience, and oncology. The company leverages proprietary platforms including MoDE (Molecular Degraders of Extracellular Proteins), TRAP (Targeted Removal of disease-driving proteins), Kv7 ion channel modulation, MATE ADC conjugation, and PKM2 modulation to advance multiple drug candidates through clinical development. The pipeline targets diseases with significant unmet medical needs such as Graves' disease, IgA nephropathy, epilepsy, obesity, Parkinson's disease, and oncology indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • BHV-1300 achieved over 80% mean reduction in pathogenic autoantibodies in Graves' hyperthyroidism patients by week 12
+4 more records
Product overview1 text field

Biohaven is a clinical-stage biopharmaceutical company developing a diversified portfolio of drug candidates across four therapeutic areas: immunology, obesity, neuroscience, and oncology. The pipeline includes extracellular protein degradation platforms (MoDE™ and TRAP™) for antibody-mediated diseases, Kv7 ion channel modulators for epilepsy, myostatin-activin inhibition for obesity, TRPM3 antagonism for pain, TYK2/JAK1 inhibition for neuroinflammatory diseases, and next-generation antibody-drug conjugates (MATE™ platform) for cancer. Key clinical-stage candidates include BHV-1300 and BHV-1400 (degraders in Phase 1b), opakalim/BHV-7000 (Kv7 activator in Phase 2/3 for epilepsy), taldefgrobep alfa (Phase 2 for obesity), BHV-8000 (Phase 3 for Parkinson's), BHV-2100 (Phase 2 for pain), BHV-1510 and BHV-1530 (ADCs in Phase 1), and BHV-8100 (Phase 1 for neurological diseases). The company also retains legacy commercial products Nurtec ODT and Zavzpret for migraine (sold to Pfizer). Biohaven operates with proven expertise in clinical execution across multiple drug development platforms.

Product and service11 records
1BHV-1300 (MoDE Degrader)
CategoryClinical-stage drug candidate
Description

Lead MoDE (Molecular Degraders of Extracellular Proteins) candidate targeting pathogenic IgG antibodies for Graves' disease. Demonstrated up to 87% IgG reduction with normalized thyroid hormones in Phase 1b trials.

2BHV-1400 (TRAP Degrader)
CategoryClinical-stage drug candidate
Description

TRAP degrader for IgA nephropathy that selectively removes galactose-deficient IgA1 (Gd-IgA1), the pathogenic antibody driver, while sparing healthy antibodies. Demonstrated up to 81% Gd-IgA1 reduction with a single subcutaneous dose.

3Opakalim (BHV-7000)
CategoryClinical-stage drug candidate
Description

Selective Kv7.2/7.3 potassium channel activator for epilepsy treatment. Structurally and pharmacologically distinct from other potassium channel activators, demonstrating minimal GABAA receptor activation with potentially better tolerability.

4Taldefgrobep Alfa (BHV-2000)
CategoryClinical-stage drug candidate
Description

Myostatin-activin pathway inhibitor targeting obesity treatment. Designed to reduce fat mass while increasing lean muscle mass, offering potential for high-quality weight loss distinct from current anti-obesity therapies.

5BHV-8000
CategoryClinical-stage drug candidate
Description

Brain-penetrant dual TYK2/JAK1 selective inhibitor for neuroinflammatory and neurodegenerative diseases including Parkinson's disease. Breaks the cycle of neuroinflammation by reducing inflammatory impacts of microglia, astrocytes, and infiltrating T-lymphocytes.

6BHV-2100
CategoryClinical-stage drug candidate
Description

Highly selective TRPM3 antagonist for pain disorders. First-in-class, orally administered molecule demonstrating potent pain reversal in preclinical models with favorable safety and pharmacokinetic properties.

7BHV-1510
CategoryClinical-stage drug candidate
Description

Next-generation Trop2 antibody-drug conjugate (ADC) for advanced or metastatic epithelial tumors. Being studied in combination with PD-1 monoclonal antibody cemiplimab in Phase 1 clinical trial.

8BHV-1530
CategoryClinical-stage drug candidate
Description

FGFR3 ADC (antibody-drug conjugate) for urothelial cancer and other tumors.

9BHV-8100
CategoryClinical-stage drug candidate
Description

Oral brain-penetrant PKM2 modulator targeting metabolic dysfunction in neurological and retinal diseases including Alzheimer's disease and multiple sclerosis. Demonstrated up to 3-fold improvement in cerebral glucose utilization in human brain models.

10Nurtec ODT (rimegepant)
CategoryLegacy commercialized product
Description

Orally disintegrating tablet for acute migraine treatment. Part of Biohaven's legacy migraine franchise that was sold to Pfizer as part of the company's asset monetization strategy.

11Zavzpret (zavegepant)
CategoryLegacy commercialized product
Description

Nasal spray for acute migraine treatment. Part of Biohaven's legacy migraine franchise sold to Pfizer.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

Collaboration announced at J.P. Morgan Healthcare Conference for advancing scientific research in key therapeutic areas. The partnership supports Biohaven's innovation engine approach combining internal R&D with academic partnerships.

Strategic tierCoreTypeTechnology or Integration
Description

Biohaven has used approximately 130 of Bexorg's disembodied human brains to test compounds including potential Parkinson's treatments. Bexorg's BrainEx technology maintains human brains for up to 24 hours for drug testing. Based on data gathered, Biohaven received FDA approval to launch a clinical trial for a brain-energy-boosting compound.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Biohaven's BHV-1510 Trop2 antibody drug conjugate is being studied in combination with Regeneron's PD-1 monoclonal antibody cemiplimab in patients with advanced solid tumors. Early-stage data presented at ESMO Immuno-Oncology Congress showed promising results.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pfizer acquired the original Biohaven including its migraine franchise (Nurtec ODT and Zavzpret). Current Biohaven was spun out from Pfizer's acquisition. Pfizer CFO Dave Denton's tenure included the Biohaven acquisition as part of an aggressive acquisition phase.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing targeted protein degradation (PROTAC) platforms. Most directly comparable to Biohaven's MoDE/TRAP degrader approach, pioneering extracellular/intracellular protein degradation technology with multiple clinical-stage candidates.

TypeBroad incumbent
Description

Established commercial-stage biopharma with diversified pipeline including rare disease and clinical-stage programs. Comparable archetype for Biohaven given shared entrepreneurial culture, broad multi-platform R&D, and track record of successful drug development and commercialization.

TypeDirect peer
Description

Clinical/commercial-stage biotech pioneering a novel therapeutic modality (RNAi) across multiple disease areas. Comparable to Biohaven given shared entrepreneurial model, multi-platform R&D approach, and novel modality strategy.

TypeDirect peer
Description

Clinical-stage biotech using targeted protein degradation (Pegasus platform) for immunology and oncology indications. Comparable to Biohaven's MoDE/TRAP platforms given shared degrader-modality approach and similar therapeutic area focus.

TypeBroad incumbent
Description

Large oncology biotech (acquired by Pfizer) specializing in antibody-drug conjugates (ADCs). Comparable to Biohaven's MATE™ ADC platform and Trop2/FGFR3 candidates BHV-1510/BHV-1530.

TypeDirect peer
Description

Clinical-stage immunology company developing FcRn inhibitors (batoclimab, IMVT-1402) for IgG-mediated autoimmune diseases including Graves' disease and myasthenia gravis, directly overlapping Biohaven's BHV-1300 MoDE program in autoimmune indications.

TypeDirect peer
Description

Clinical-stage CNS biotech (acquired by BMS) focused on neuropsychiatric indications including schizophrenia. Comparable to Biohaven's pre-MDD-failure psychiatry ambitions and CNS specialization model.

TypeDirect peer
Description

Clinical-stage biotech focused on genetic diseases and rare disease therapeutics with multiple late-stage programs. Comparable business model to Biohaven through multiple platform approaches targeting niche indications, often using novel mechanisms of action.

TypeDirect peer
Description

Clinical-stage neurology biotech with epilepsy programs. Directly comparable to Biohaven's BHV-7000 opakalim program; both companies developing novel CNS-targeted epilepsy treatments with Phase 2/3 readouts.

TypeDirect peer
Description

CNS-focused clinical-stage biopharma (now private post-Biogen acquisition) developing neuroactive therapeutics. Highly comparable to Biohaven's Kv7/PKM2 neurology pipeline and neuroscience therapeutic area focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biohaven

Clinical-stage Biopharmaceuticalsbiohaven.com

Biohaven is a clinical-stage biopharmaceutical company developing novel therapies across immunology, obesity, neuroscience, and oncology using proprietary platforms including MoDE and TRAP protein degraders, Kv7 ion channel modulators, and MATE ADC technology.

What Biohaven does

Biohaven is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut (incorporated as Biohaven, Ltd. in the British Virgin Islands, with U.S. operations through Biohaven Pharmaceuticals, Inc.), that was spun out of Pfizer's 2023 acquisition of the original Biohaven and concurrently listed on the NYSE under ticker BHVN. The company employs 251-500 staff across offices in New Haven, Cambridge, and Pittsburgh, and is led by Chairman & CEO Vlad Coric, M.D. Biohaven is developing a diversified pipeline of drug candidates across four therapeutic areas — immunology, obesity, neuroscience, and oncology — supported by five proprietary technology platforms: MoDE (Molecular Degraders of Extracellular Proteins), TRAP (Targeted Removal via the asialoglycoprotein receptor), Kv7 ion channel modulation, MATE antibody-drug conjugate chemistry, and PKM2 metabolic modulation.

The pipeline includes late-stage clinical candidates BHV-1300 (MoDE degrader for Graves' disease, >80% pathogenic IgG reduction), BHV-1400 (TRAP degrader for IgA nephropathy, up to 81% Gd-IgA1 reduction), opakalim/BHV-7000 (Kv7.2/7.3 activator for epilepsy), taldefgrobep alfa (myostatin-activin inhibitor for obesity), BHV-1510 (Trop2 ADC combined with Regeneron's cemiplimab in solid tumors), BHV-1530 (FGFR3 ADC in urothelial cancer), BHV-8000 (TYK2/JAK1 inhibitor in Parkinson's), BHV-2100 (TRPM3 antagonist in pain), and first-in-human BHV-8100 (oral PKM2 modulator). A preclinical MoDE/TRAP portfolio extends into myasthenia gravis, Type 1 diabetes, pemphigus, and cardiomyopathies.

Biohaven generates no product revenue as of Q1 2026 (net loss of $130.5 million, a 41% improvement from $221.7 million in Q1 2025) and has no commercialized products following the divestiture of its legacy migraine franchise (Nurtec ODT, Zavzpret) to Pfizer. The company is pre-revenue and intends to monetize through future U.S. pharmaceutical distribution (specialty pharmacies, wholesalers, hospital networks) and potential licensing or co-development partnerships with large pharma, evidenced by its ongoing Regeneron combination collaboration. Strategic cost optimization announced in 2026 targets a ~60% reduction in annual direct R&D spend as the company prioritizes late-stage degraders, Kv7, and obesity programs following a November 2025 FDA Complete Response Letter on troriluzole for spinocerebellar ataxia and a December 2025 Phase 2 failure of opakalim in major depressive disorder.

Biohaven firmographics

Firmographics
Name
Biohaven
Legal name
Biohaven, Ltd.
Website
https://biohaven.com
Company type
Public
Founded year
2023
Operating status
Operating
Headcount range
251–500 employees
Short description
Biohaven is a clinical-stage biopharmaceutical company developing novel therapies across immunology, obesity, neuroscience, and oncology using proprietary platforms including MoDE and TRAP protein degraders, Kv7 ion channel modulators, and MATE ADC technology.
Ownership category
akta.pro rank

Biohaven industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Clinical-stage biopharmaceutical
  • Protein degradation therapeutics
  • Autoimmune disease treatments
  • Epilepsy drug development
  • Antibody-drug conjugates

Where Biohaven is headquartered

Location

Headquarters

HQ city
New Haven
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Biohaven business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Biohaven is a clinical-stage biopharmaceutical company with no current revenue from product sales. The company is developing multiple late-stage clinical candidates and has not yet commercialized any products. Historically, the company developed migraine treatments (Nurtec ODT and Zavzpret) that were sold to Pfizer as part of the original Biohaven acquisition.
  2. Drug Development Partnerships/Licensing: Potential future revenue from licensing agreements or co-development partnerships for its proprietary platforms and pipeline candidates. The company may pursue partnerships for global commercialization of its clinical candidates.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Biohaven product offering

Product offering

Core offering

Biohaven is a clinical-stage biopharmaceutical company developing life-changing treatments across immunology, obesity, neuroscience, and oncology. The company leverages proprietary platforms including MoDE (Molecular Degraders of Extracellular Proteins), TRAP (Targeted Removal of disease-driving proteins), Kv7 ion channel modulation, MATE ADC conjugation, and PKM2 modulation to advance multiple drug candidates through clinical development. The pipeline targets diseases with significant unmet medical needs such as Graves' disease, IgA nephropathy, epilepsy, obesity, Parkinson's disease, and oncology indications.

Product overview

Biohaven is a clinical-stage biopharmaceutical company developing a diversified portfolio of drug candidates across four therapeutic areas: immunology, obesity, neuroscience, and oncology. The pipeline includes extracellular protein degradation platforms (MoDE™ and TRAP™) for antibody-mediated diseases, Kv7 ion channel modulators for epilepsy, myostatin-activin inhibition for obesity, TRPM3 antagonism for pain, TYK2/JAK1 inhibition for neuroinflammatory diseases, and next-generation antibody-drug conjugates (MATE™ platform) for cancer. Key clinical-stage candidates include BHV-1300 and BHV-1400 (degraders in Phase 1b), opakalim/BHV-7000 (Kv7 activator in Phase 2/3 for epilepsy), taldefgrobep alfa (Phase 2 for obesity), BHV-8000 (Phase 3 for Parkinson's), BHV-2100 (Phase 2 for pain), BHV-1510 and BHV-1530 (ADCs in Phase 1), and BHV-8100 (Phase 1 for neurological diseases). The company also retains legacy commercial products Nurtec ODT and Zavzpret for migraine (sold to Pfizer). Biohaven operates with proven expertise in clinical execution across multiple drug development platforms.

Differentiator

Problem solved

Functional benefit

Products and services

  • BHV-1300 (MoDE Degrader) Lead MoDE (Molecular Degraders of Extracellular Proteins) candidate targeting pathogenic IgG antibodies for Graves' disease. Demonstrated up to 87% IgG reduction with normalized thyroid hormones in Phase 1b trials.
  • BHV-1400 (TRAP Degrader) TRAP degrader for IgA nephropathy that selectively removes galactose-deficient IgA1 (Gd-IgA1), the pathogenic antibody driver, while sparing healthy antibodies. Demonstrated up to 81% Gd-IgA1 reduction with a single subcutaneous dose.
  • Opakalim (BHV-7000) Selective Kv7.2/7.3 potassium channel activator for epilepsy treatment. Structurally and pharmacologically distinct from other potassium channel activators, demonstrating minimal GABAA receptor activation with potentially better tolerability.
  • Taldefgrobep Alfa (BHV-2000) Myostatin-activin pathway inhibitor targeting obesity treatment. Designed to reduce fat mass while increasing lean muscle mass, offering potential for high-quality weight loss distinct from current anti-obesity therapies.
  • BHV-8000 Brain-penetrant dual TYK2/JAK1 selective inhibitor for neuroinflammatory and neurodegenerative diseases including Parkinson's disease. Breaks the cycle of neuroinflammation by reducing inflammatory impacts of microglia, astrocytes, and infiltrating T-lymphocytes.
  • BHV-2100 Highly selective TRPM3 antagonist for pain disorders. First-in-class, orally administered molecule demonstrating potent pain reversal in preclinical models with favorable safety and pharmacokinetic properties.
  • BHV-1510 Next-generation Trop2 antibody-drug conjugate (ADC) for advanced or metastatic epithelial tumors. Being studied in combination with PD-1 monoclonal antibody cemiplimab in Phase 1 clinical trial.
  • BHV-1530 FGFR3 ADC (antibody-drug conjugate) for urothelial cancer and other tumors.
  • BHV-8100 Oral brain-penetrant PKM2 modulator targeting metabolic dysfunction in neurological and retinal diseases including Alzheimer's disease and multiple sclerosis. Demonstrated up to 3-fold improvement in cerebral glucose utilization in human brain models.
  • Nurtec ODT (rimegepant) Orally disintegrating tablet for acute migraine treatment. Part of Biohaven's legacy migraine franchise that was sold to Pfizer as part of the company's asset monetization strategy.
  • Zavzpret (zavegepant) Nasal spray for acute migraine treatment. Part of Biohaven's legacy migraine franchise sold to Pfizer.

Quantifiable outcome

  • BHV-1300 achieved over 80% mean reduction in pathogenic autoantibodies in Graves' hyperthyroidism patients by week 12
  • +4 more outcomes

Companies that use Biohaven

Customer profile

Named customers6 records

Segments1 record

Ideal customer profiles3 records

Biohaven technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Biohaven partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • King Abdullah University of Science and TechnologyminorStrategic or Co-development Partner · 12 January 2026Collaboration announced at J.P. Morgan Healthcare Conference for advancing scientific research in key therapeutic areas. The partnership supports Biohaven's innovation engine approach combining internal R&D with academic partnerships.
  • BexorgcoreTechnology or IntegrationBiohaven has used approximately 130 of Bexorg's disembodied human brains to test compounds including potential Parkinson's treatments. Bexorg's BrainEx technology maintains human brains for up to 24 hours for drug testing. Based on data gathered, Biohaven received FDA approval to launch a clinical trial for a brain-energy-boosting compound.
  • RegeneroncoreStrategic or Co-development PartnerBiohaven's BHV-1510 Trop2 antibody drug conjugate is being studied in combination with Regeneron's PD-1 monoclonal antibody cemiplimab in patients with advanced solid tumors. Early-stage data presented at ESMO Immuno-Oncology Congress showed promising results.
  • PfizercoreStrategic or Co-development PartnerPfizer acquired the original Biohaven including its migraine franchise (Nurtec ODT and Zavzpret). Current Biohaven was spun out from Pfizer's acquisition. Pfizer CFO Dave Denton's tenure included the Biohaven acquisition as part of an aggressive acquisition phase.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Biohaven competitors and assessment

Company assessment

Direct peers

  • Arvinas: Clinical-stage biotech developing targeted protein degradation (PROTAC) platforms. Most directly comparable to Biohaven's MoDE/TRAP degrader approach, pioneering extracellular/intracellular protein degradation technology with multiple clinical-stage candidates.
  • Alnylam Pharmaceuticals: Clinical/commercial-stage biotech pioneering a novel therapeutic modality (RNAi) across multiple disease areas. Comparable to Biohaven given shared entrepreneurial model, multi-platform R&D approach, and novel modality strategy.
  • Kymera Therapeutics: Clinical-stage biotech using targeted protein degradation (Pegasus platform) for immunology and oncology indications. Comparable to Biohaven's MoDE/TRAP platforms given shared degrader-modality approach and similar therapeutic area focus.
  • Immunovant: Clinical-stage immunology company developing FcRn inhibitors (batoclimab, IMVT-1402) for IgG-mediated autoimmune diseases including Graves' disease and myasthenia gravis, directly overlapping Biohaven's BHV-1300 MoDE program in autoimmune indications.
  • Karuna Therapeutics: Clinical-stage CNS biotech (acquired by BMS) focused on neuropsychiatric indications including schizophrenia. Comparable to Biohaven's pre-MDD-failure psychiatry ambitions and CNS specialization model.
  • BridgeBio Pharma: Clinical-stage biotech focused on genetic diseases and rare disease therapeutics with multiple late-stage programs. Comparable business model to Biohaven through multiple platform approaches targeting niche indications, often using novel mechanisms of action.
  • Xenon Pharmaceuticals: Clinical-stage neurology biotech with epilepsy programs. Directly comparable to Biohaven's BHV-7000 opakalim program; both companies developing novel CNS-targeted epilepsy treatments with Phase 2/3 readouts.
  • Sage Therapeutics: CNS-focused clinical-stage biopharma (now private post-Biogen acquisition) developing neuroactive therapeutics. Highly comparable to Biohaven's Kv7/PKM2 neurology pipeline and neuroscience therapeutic area focus.

Broad incumbents

  • Vertex Pharmaceuticals: Established commercial-stage biopharma with diversified pipeline including rare disease and clinical-stage programs. Comparable archetype for Biohaven given shared entrepreneurial culture, broad multi-platform R&D, and track record of successful drug development and commercialization.
  • Seagen: Large oncology biotech (acquired by Pfizer) specializing in antibody-drug conjugates (ADCs). Comparable to Biohaven's MATE™ ADC platform and Trop2/FGFR3 candidates BHV-1510/BHV-1530.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Biohaven social profiles

Digital presence

Biohaven financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biohaven leadership team

Management profile

Number of profiles

Profiles2 records

Biohaven funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biohaven M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biohaven

What does Biohaven do?

Biohaven is a clinical-stage biopharmaceutical company developing life-changing treatments across immunology, obesity, neuroscience, and oncology. The company leverages proprietary platforms including MoDE (Molecular Degraders of Extracellular Proteins), TRAP (Targeted Removal of disease-driving proteins), Kv7 ion channel modulation, MATE ADC conjugation, and PKM2 modulation to advance multiple drug candidates through clinical development. The pipeline targets diseases with significant unmet medical needs such as Graves' disease, IgA nephropathy, epilepsy, obesity, Parkinson's disease, and oncology indications.

Is Biohaven a public or private company?

Biohaven is a public company. It is classified as public and is currently operating.

When was Biohaven founded?

Biohaven was founded in 2023. It employs 251 to 500 people.

Where is Biohaven based?

Biohaven is headquartered in New Haven, United States, in the North America region.

How does Biohaven make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are drug Development Partnerships/Licensing.

Who are Biohaven's main competitors?

Direct peers on record are Arvinas, Alnylam Pharmaceuticals, Kymera Therapeutics, Immunovant, Karuna Therapeutics, BridgeBio Pharma, Xenon Pharmaceuticals and Sage Therapeutics. Broad incumbents are Vertex Pharmaceuticals and Seagen.

Does Biohaven have an API?

No public API is recorded for Biohaven.

What industry is Biohaven in?

Biohaven's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanBiohaven's $400M SK Biopharma license awaits closingBiohaven reported Q3 2026 results, including a $400 million SK Biopharma license for opakalim and an $80 million upfront from Ono for its MoDE degrader portfolio. The company also advanced BHV-1300 in Graves' disease and BHV-1400 in IgA nephropathy, with opakalim topline data expected in H2 2026.Seeking AlphaBiohaven Stock Soars As FDA Accepts Vyglyxia Resubmission - This Plot Is Too Thick (BHVN)Biohaven's stock rose over 25% after the FDA accepted its NDA resubmission for Vyglyxia (troriluzole) for spinocerebellar ataxia, assigning a user fee goal date in Q1 2027. The drug showed a 50-70% slower disease progression in a 3-year study, but the company has not disclosed the news in recent investor communications.Simply Wall StHow Biohaven Licensing Deal At Ono Pharmaceutical Stock Has Changed Its Investment StoryOno Pharmaceutical secured exclusive rights to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan, and ASEAN. The deal includes up to US$100 million in near-term payments and about 20% royalties on future net sales. The agreement may refresh medium-term catalysts if trials and launches progress cleanly.Stock TitanBiohaven signs Ono licensing deal for up to $100MBiohaven entered a licensing agreement with Ono Pharma to develop and commercialize its MoDE IgG degraders in Japan, South Korea, Taiwan, and ASEAN. Ono pays Biohaven up to $100 million, including $80 million upfront and 20% royalties on net sales. Biohaven retains rights outside the licensed territory.PR NewswireBiohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' DiseaseBiohaven licensed its extracellular IgG degraders to Ono Pharma for Japan, South Korea, Taiwan, and ASEAN. Ono will pay up to $100 million upfront, including $80 million at closing, plus 20% royalties. Biohaven retains rights outside the licensed territory.Law360Yale, Biohaven Seek $23M Atty Fee After Trade Secrets WinYale University and Biohaven Therapeutics sought over $23 million in attorney fees plus $2 million each in exemplary damages after winning a $4 million trial verdict. Both parties also seek a new trial to readdress damages on trade secrets and contract breach claims.Clinical Trials ArenaJ&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar winJ&J's $14.6bn Intra-Cellular acquisition continues to pay off as Caplyta met its primary endpoint in a Phase III trial for bipolar I manic episodes. The study showed a 4.8-point greater YMRS reduction versus placebo and twice as many patients achieved clinical response. A second pivotal trial has concluded but data are not yet announced.Clinical Trials ArenaBiohaven’s epilepsy drug hit with FDA clinical holdThe FDA placed a partial clinical hold on Biohaven's epilepsy candidate opakalim after safety signals from nonclinical metabolite testing. Biohaven must pause new enrolment but can continue dosing existing patients, with RISE-3 fully enrolled and expecting a readout in H2 2026. The hold follows SK Biopharmaceuticals' $350m acquisition of global rights.MorningstarBiohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)Biohaven shares fell 14.73% on September 10, 2026 after the FDA placed a partial clinical hold on new-patient enrollment in its BHV-7000/opakalim epilepsy trials. The FDA cited insufficient information on a specific metabolite to assess risks. Dosing continues for already randomized patients.KoreajoongangdailyFDA partially halts trials of SK Biopharmaceuticals’ epilepsy drug candidateThe FDA placed SK Biopharmaceuticals' epilepsy drug candidate Opakalim on a partial clinical hold after observing toxicity in a rodent study. Dosing continues for enrolled patients, and Biohaven plans to submit additional nonclinical data to seek lifting of the hold. The RISE 3 trial schedule remains unchanged.